Stableford Capital II LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 0.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,331 shares of the conglomerate’s stock after selling 45 shares during the quarter. Stableford Capital II LLC’s holdings in Danaher were worth $1,224,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Wedge Capital Management L L P NC lifted its stake in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares during the period. Meridian Financial Partners LLC lifted its position in shares of Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares during the period. Kovack Advisors Inc. grew its holdings in shares of Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC raised its stake in shares of Danaher by 1.2% in the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC lifted its position in Danaher by 0.9% in the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after purchasing an additional 42 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Danaher Trading Down 0.2 %
DHR stock opened at $222.56 on Friday. The business has a fifty day moving average of $235.40 and a 200-day moving average of $253.07. The company has a market cap of $160.75 billion, a P/E ratio of 42.15, a PEG ratio of 4.22 and a beta of 0.83. Danaher Co. has a twelve month low of $221.34 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, equities research analysts expect that Danaher Co. will post 8.15 EPS for the current year.
Danaher Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- What Do S&P 500 Stocks Tell Investors About the Market?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.